Robust dPCR Hyper-Plexing Approach by Color Combination for Detection of 17 ESR1 Mutations in Breast Cancer Patient Samples.
1/5 보강
Digital PCR has seen increasing adoption in recent years since it overcomes most of the main technical limitations of real-time PCR.
APA
Ursuegui S, Donzier J, et al. (2026). Robust dPCR Hyper-Plexing Approach by Color Combination for Detection of 17 ESR1 Mutations in Breast Cancer Patient Samples.. Methods in molecular biology (Clifton, N.J.), 2969, 101-121. https://doi.org/10.1007/978-1-0716-4767-7_7
MLA
Ursuegui S, et al.. "Robust dPCR Hyper-Plexing Approach by Color Combination for Detection of 17 ESR1 Mutations in Breast Cancer Patient Samples.." Methods in molecular biology (Clifton, N.J.), vol. 2969, 2026, pp. 101-121.
PMID
41073861 ↗
Abstract 한글 요약
Digital PCR has seen increasing adoption in recent years since it overcomes most of the main technical limitations of real-time PCR. However, the level of multiplexing remains limited when facing the need to develop approaches that can detect multiple targets in a single reaction with a high sensitivity to obtain a more complete genetic characterization of samples. This need concerns most molecular biology applications, but it is especially valuable in fields such as oncology, for which it is often necessary to detect numerous specific mutations, particularly those involving hotspots, in order to adapt a treatment, monitor the efficacy of a drug, and detect resistance mutations. This is the case of the ESR1 gene in breast cancer, where numerous mutations can be responsible for mechanisms of resistance to the backbone therapy. In this sense, the implementation of color combination using Crystal Digital PCR® allows high levels of multiplexing to be achieved, while maintaining simplicity and robustness of analysis. This approach has been successfully applied to the detection of 17 ESR1 mutations in a single assay.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.